96 related articles for article (PubMed ID: 15351863)
1. Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Haemost; 2004 Sep; 92(3):646-53. PubMed ID: 15351863
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Atherosclerosis; 2007 Jan; 190(1):199-204. PubMed ID: 16510149
[TBL] [Abstract][Full Text] [Related]
3. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients.
Pawlak K; Naumnik B; Brzósko S; Pawlak D; Myśliwiec M
Am J Nephrol; 2004; 24(1):154-61. PubMed ID: 14726627
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients.
Pawlak K; Borawski J; Naumnik B; Mysliwiec M
Thromb Res; 2003 Mar; 109(5-6):247-51. PubMed ID: 12818246
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress influences CC-chemokine levels in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Nephron Physiol; 2004; 96(4):p105-12. PubMed ID: 15122056
[TBL] [Abstract][Full Text] [Related]
9. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
Pawlak K; Zolbach K; Borawski J; Mysliwiec M; Kovalchuk O; Chyczewski L; Pawlak D
Thromb Res; 2008; 123(1):166-70. PubMed ID: 18452978
[TBL] [Abstract][Full Text] [Related]
10. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
11. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
12. [Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure].
Pawlak K; Pawlak D; Myśliwiec M
Pol Arch Med Wewn; 2005 Jan; 113(1):21-6. PubMed ID: 16130597
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
14. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
[TBL] [Abstract][Full Text] [Related]
15. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients.
Borawski J; Pawlak K; Naumnik B; Myśliwiec M
Ren Fail; 2002 Nov; 24(6):825-37. PubMed ID: 12472204
[TBL] [Abstract][Full Text] [Related]
16. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2004; 24(6):635-40. PubMed ID: 15627719
[TBL] [Abstract][Full Text] [Related]
17. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.
Pawlak K; Domaniewski T; Mysliwiec M; Pawlak D
Atherosclerosis; 2009 May; 204(1):309-14. PubMed ID: 18823890
[TBL] [Abstract][Full Text] [Related]
18. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.
Pawlak K; Brzosko S; Mysliwiec M; Pawlak D
Atherosclerosis; 2009 Jun; 204(2):561-6. PubMed ID: 19027117
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes.
Pawlak K; Pawlak D; Mysliwiec M
Nephron Clin Pract; 2007; 107(1):c20-5. PubMed ID: 17671395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
